Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

114
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
114
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

10.3K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
10.3K
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

112
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
112
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.4K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.4K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

10.8K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
10.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characterization of Fluorophore-Quencher Pairs for Distance-Dependent Molecular Sensing in Photoacoustic Imaging.

Chemical & biomedical imaging·2026
Same author

Stress unmasks impaired endocrine coordination of glucose metabolism in dystrophin deficiency.

bioRxiv : the preprint server for biology·2026
Same author

Next-Gen <sup>18</sup>F-Relay Reagent: Optimising [<sup>18</sup>F]Ethanesulfonyl Fluoride.

International journal of molecular sciences·2026
Same author

Collagen-targeted tracers for molecular imaging of atrial fibrosis and sensitive detection of atrial fibrillation.

NPJ cardiovascular health·2026
Same author

Novel immunotheranostic FAP-inhibitor target modules for imaging and elimination of FAP-positive cells by UniCAR T-cells.

Oncoimmunology·2025
Same author

Trafficking Glycogen Nanoparticles through Lymph Node Tissues for the Delivery of Small and Large Bioactive Molecules.

ACS nano·2025

Related Experiment Video

Updated: Apr 6, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

23.5K

Multifunctional Thrombin-Activatable Polymer Capsules for Specific Targeting to Activated Platelets.

Sylvia T Gunawan1, Kristian Kempe2, Thomas Bonnard3

  • 1ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, and the Department of Chemical and Biomolecular Engineering, The University of Melbourne, Parkville, Victoria, 3010, Australia.

Advanced Materials (Deerfield Beach, Fla.)
|August 5, 2015
PubMed
Summary
This summary is machine-generated.

Smart polymer capsules target activated platelets via glycoprotein IIb/IIIa. Upon thrombin degradation, these capsules release urokinase plasminogen activator specifically at acute thrombosis sites.

Keywords:
antibodiesdrug deliveryplasminogen activatorspolymer carriersthrombosis

More Related Videos

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
07:13

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Published on: May 24, 2024

1.0K
Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

1.3K

Related Experiment Videos

Last Updated: Apr 6, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

23.5K
Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
07:13

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Published on: May 24, 2024

1.0K
Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

1.3K

Area of Science:

  • Biomaterials Science
  • Polymer Chemistry
  • Nanotechnology

Background:

  • Platelet activation is crucial in acute thrombosis.
  • Targeting activated platelets is a key strategy for antithrombotic therapy.
  • Current therapies may lack specificity, leading to systemic side effects.

Purpose of the Study:

  • To develop smart, multifunctional polymer capsules for targeted drug delivery in thrombosis.
  • To engineer capsules that respond to specific biological triggers at the thrombosis site.
  • To achieve localized release of therapeutic agents to enhance efficacy and reduce side effects.

Main Methods:

  • Synthesis of poly(2-oxazoline) (POx)-based polymer capsules.
  • Functionalization of capsules to target glycoprotein (GP) IIb/IIIa on activated platelets.
  • Incorporation of urokinase plasminogen activator (uPA) as a payload.
  • Demonstration of capsule degradation by thrombin, a serine protease present in thrombi.
  • In vitro or in vivo validation of targeted release at thrombosis sites.

Main Results:

  • The developed POx-based capsules specifically bind to activated platelets expressing GP IIb/IIIa.
  • Capsule degradation and subsequent release of uPA are triggered by thrombin.
  • Drug release is localized to the area of acute thrombosis, minimizing off-target effects.
  • The smart delivery system demonstrates potential for site-specific antithrombotic therapy.

Conclusions:

  • Smart POx-based polymer capsules offer a promising platform for targeted drug delivery in thrombosis.
  • The system's responsiveness to thrombin ensures localized release of urokinase plasminogen activator.
  • This targeted approach holds potential for improved treatment of acute thrombotic events.